AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA NDA

REDWOOD CITY, Calif., Oct. 12, 2017 /PRNewswire/-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news